Literature DB >> 24850323

Incidence, immunological and clinical characteristics of reactivation of latent Toxoplasma gondii infection in HIV-infected patients.

P Kodym1, M Malý2, O Beran3, D Jilich3, H Rozsypal3, L Machala4, M Holub3.   

Abstract

To determine changes in incidence of reactivation of Toxoplasma gondii infection, manifesting as toxoplasmic encephalitis, and to assess the immunological mechanisms controlling reactivation in HIV-infected patients, a Czech cohort of 502 HIV/T. gondii co-infected patients was followed for 2909·3 person-years. The incidence of toxoplasmic encephalitis between the periods before and after the introduction of combination antiretroviral therapy (cART) was compared. Toxoplasmic encephalitis was diagnosed in 21 patients. In those patients the geometric mean value of CD4+ T lymphocytes was 12·6 times lower than in patients with non-reactivated T. gondii infection but an additionally significant decline in CD8+ T lymphocytes (3·3-fold) and natural killer cells (4·3-fold) was observed. This confirms the significance of these parameters. A twelvefold decrease in Toxoplasma reactivation incidence (40·2 vs. 3·4/1000 person-years) between monitored periods was seen. In the cART era, Toxoplasma reactivation was observed only in patients with unrecognized HIV infection or refusing therapy.

Entities:  

Keywords:  Encephalitis; HIV/AIDS; Toxoplasma gondii; immunology; incidence

Mesh:

Year:  2014        PMID: 24850323      PMCID: PMC9507066          DOI: 10.1017/S0950268814001253

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  37 in total

1.  Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. The Adult/Adolescent Spectrum of Disease Group.

Authors:  J L Jones; D L Hanson; S Y Chu; C A Ciesielski; J E Kaplan; J W Ward; T R Navin
Journal:  AIDS       Date:  1996-10       Impact factor: 4.177

2.  Congenital toxoplasmosis from an HIV-infected woman as a result of reactivation.

Authors:  C Bachmeyer; G Mouchnino; P Thulliez; L Blum
Journal:  J Infect       Date:  2005-07-25       Impact factor: 6.072

3.  Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy.

Authors:  S Bertschy; M Opravil; M Cavassini; E Bernasconi; V Schiffer; P Schmid; M Flepp; J-P Chave; A Christen; H Furrer
Journal:  Clin Microbiol Infect       Date:  2006-07       Impact factor: 8.067

Review 4.  Toxoplasmic encephalitis in patients with AIDS.

Authors:  D M Israelski; J S Remington
Journal:  Infect Dis Clin North Am       Date:  1988-06       Impact factor: 5.982

5.  [Value and limitations of toxoplasmosis serology in HIV patients].

Authors:  F Derouin; P Thulliez; Y J Garin
Journal:  Pathol Biol (Paris)       Date:  1991-04

6.  Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.

Authors:  P M Girard; R Landman; C Gaudebout; R Olivares; A G Saimot; P Jelazko; C Gaudebout; A Certain; F Boué; E Bouvet
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

7.  Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey.

Authors:  C Rabaud; T May; C Amiel; C Katlama; C Leport; P Ambroise-Thomas; P Canton
Journal:  Medicine (Baltimore)       Date:  1994-11       Impact factor: 1.889

8.  Incidence and clinical and immunological characteristics of primary Toxoplasma gondii infection in HIV-infected patients.

Authors:  Ladislav Machala; Marek Malý; Ondřej Beran; David Jilich; Petr Kodym
Journal:  Int J Infect Dis       Date:  2013-05-11       Impact factor: 3.623

9.  Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice.

Authors:  E Y Denkers; R T Gazzinelli; D Martin; A Sher
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

10.  Redefining chronic toxoplasmosis--a T cell exhaustion perspective.

Authors:  Rajarshi Bhadra; Imtiaz A Khan
Journal:  PLoS Pathog       Date:  2012-10-11       Impact factor: 6.823

View more
  19 in total

1.  The IL-12- and IL-23-Dependent NK Cell Response Is Essential for Protective Immunity against Secondary Toxoplasma gondii Infection.

Authors:  Daria L Ivanova; Tiffany M Mundhenke; Jason P Gigley
Journal:  J Immunol       Date:  2019-10-11       Impact factor: 5.422

2.  Prevalence of Toxoplasma gondii infection in HIV-infected patients and food animals and direct genotyping of T. gondii isolates, Southern Ghana.

Authors:  Faustina Pappoe; Weisheng Cheng; Lin Wang; Yuanling Li; Dorcas Obiri-Yeboah; Samuel Victor Nuvor; Henock Ambachew; Xiaodong Hu; Qingli Luo; Deyong Chu; Yuanhong Xu; Jilong Shen
Journal:  Parasitol Res       Date:  2017-04-22       Impact factor: 2.289

3.  Latent Toxoplasma gondii Infection and Associated Risk Factors among HIV-Infected Individuals at Arba Minch Hospital, South Ethiopia.

Authors:  Tsegaye Yohanes; Serkadis Debalke; Endalew Zemene
Journal:  AIDS Res Treat       Date:  2014-11-09

4.  Intranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice.

Authors:  Zhuanzhuan Liu; Litian Yin; Yaqing Li; Fei Yuan; Xiaofan Zhang; Jiazhi Ma; Hongmei Liu; Yanjuan Wang; Kuiyang Zheng; Jianping Cao
Journal:  BMC Immunol       Date:  2016-10-06       Impact factor: 3.615

Review 5.  Innate recognition of Toxoplasma gondii in humans involves a mechanism distinct from that utilized by rodents.

Authors:  Alan Sher; Kevin Tosh; Dragana Jankovic
Journal:  Cell Mol Immunol       Date:  2016-05-09       Impact factor: 11.530

6.  Toxoplasmosis with chorioretinitis in an HIV-infected child with no visual complaints-importance of fundus examination.

Authors:  Noella Maria Delia Pereira; Ira Shah; Mamatha Lala
Journal:  Oxf Med Case Reports       Date:  2017-01-03

7.  Acute disseminated encephalomyelitis and reactivation of cerebral toxoplasmosis in a child: Case report.

Authors:  Sami Bannoura; Rana El Hajj; Ibrahim Khalifeh; Hiba El Hajj
Journal:  IDCases       Date:  2018-08-06

8.  Serological Responses to Toxoplasma gondii and Matrix Antigen 1 Predict the Risk of Subsequent Toxoplasmic Encephalitis in People Living With Human Immunodeficiency Virus (HIV).

Authors:  Jianchun Xiao; Fiona Bhondoekhan; Eric C Seaberg; Otto Yang; Valentina Stosor; Joseph B Margolick; Robert H Yolken; Raphael P Viscidi
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

9.  The Effect of Latent Toxoplasma gondii Infection on the Immune Response in HIV-Infected Patients.

Authors:  Ondrej Beran; Petr Kodym; Marek Maly; Alzbeta Davidova; Gabriela Reinvartova; David Jilich; Michal Holub; Hanus Rozsypal
Journal:  Biomed Res Int       Date:  2015-07-12       Impact factor: 3.411

10.  Seroprevalence of Toxoplasma gondii infection among patients with hand, foot and mouth disease in Henan, China: a hospital-based study.

Authors:  Shuai Wang; Chunwei Lan; Luwen Zhang; Haizhu Zhang; Zhijun Yao; Dong Wang; Jingbo Ma; Jiarong Deng; Shiguo Liu
Journal:  Infect Dis Poverty       Date:  2015-12-10       Impact factor: 4.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.